259 related articles for article (PubMed ID: 22899627)
21. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
22. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
23. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
24. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
Baylin SB; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
[No Abstract] [Full Text] [Related]
25. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
26. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
27. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
28. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
29. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
30. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications.
Damm F; Thol F; Kosmider O; Kade S; Löffeld P; Dreyfus F; Stamatoullas-Bastard A; Tanguy-Schmidt A; Beyne-Rauzy O; de Botton S; Guerci-Bresler A; Göhring G; Schlegelberger B; Ganser A; Bernard OA; Fontenay M; Heuser M
Leukemia; 2012 May; 26(5):1137-40. PubMed ID: 22064355
[No Abstract] [Full Text] [Related]
31. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
32. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA; Watts J; Radinoff A; Sangerman MA; Cerrano M; Lopez PF; Zeidner JF; Campelo MD; Graux C; Liesveld J; Selleslag D; Tzvetkov N; Fram RJ; Zhao D; Bell J; Friedlander S; Faller DV; Adès L
Leukemia; 2021 Jul; 35(7):2119-2124. PubMed ID: 33483617
[No Abstract] [Full Text] [Related]
33. [New tools and treatments in myelodysplastic syndromes].
Cluzeau T; Fenaux P
Rev Med Interne; 2013 Mar; 34(3):159-67. PubMed ID: 22766158
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
[TBL] [Abstract][Full Text] [Related]
35. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
Maeda Y
Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
[No Abstract] [Full Text] [Related]
36. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
37. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
Gill H
Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
[TBL] [Abstract][Full Text] [Related]
38. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert M
Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
[No Abstract] [Full Text] [Related]
39. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
[No Abstract] [Full Text] [Related]
40. [Novel therapeutics for myelodysplastic syndromes].
Tohyama K
Rinsho Ketsueki; 2011 Oct; 52(10):1535-43. PubMed ID: 21971230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
